Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that finasteride users had a very low rate of psychiatric side effects, with no significant increase in BPH patients and a slight increase in anxiety and depression among AGA patients.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This article critiques a study on finasteride use among individuals with benign prostatic hyperplasia and androgenetic alopecia, highlighting the flawed methodology and potential confounding effects of hair loss on mental health, which confuses interpretation of psychiatric risk.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

In this study, Saw Palmetto at a physiological dose partially inhibited 5-α-reductase and improved hormonal balance, inflammation, and mitochondrial function, with synergy observed when combined with Lycopene, L-Arginine, and Astaxanthin, enhancing male prostatic and endocrine health without endocrine side effects.

This study reported that Saw Palmetto, at a physiological dose, partially inhibits 5-alpha-reductase and, when combined with Lycopene, L-Arginine, and Astaxanthin, demonstrates a synergistic effect in restoring hormonal balance, reducing inflammation, and improving hair density, urinary flow, and oxidative biomarkers in related male health conditions.

This study found that the Keyora Lycopene 23 in 1 formulation may improve various aspects of male endocrine and reproductive health by targeting oxidative stress, nitric oxide deficiency, and hormonal imbalance.

In this study, the researchers introduced the Keyora Lycopene 23 in 1 formulation, demonstrating its potential to improve male endocrine and reproductive health by addressing oxidative stress, nitric oxide deficiency, androgen imbalance, and mitochondrial dysfunction through a comprehensive multi-nutrient approach.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This review details the prevalence and management of ejaculatory disorders in men with benign prostatic hyperplasia-related urinary symptoms and highlights the importance of preserving peri-montanal tissue during treatment to maintain antegrade ejaculation.

In this study, researchers found that androgen receptor gene polymorphism is associated with higher androgenetic alopecia grades and PSA levels in men with benign prostatic hyperplasia, but not with prostate cancer.

This cohort study found no overall increased risk of suicidal behaviors with finasteride versus dutasteride in men aged 50 and older, but suggested potential risk for those with a history of mood disorders.

This review discusses the role of DHT in male sexual differentiation and fertility in individuals with 5α-reductase-2 deficiency, reporting no new clinical results.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

In this study, kolaviron and quercetin were found to reverse elevated biomarkers associated with testosterone-induced benign prostatic hyperplasia in Wistar rats, with both treatments effectively increasing HDL-c levels, though quercetin did not significantly affect triglyceride levels.

This review discusses the potential role of steroid 5α-reductase inhibitors in treating neuropsychiatric disorders related to dopaminergic hyperreactivity but reports no new clinical results.

This study introduces three spectrophotometric techniques for accurately determining finasteride and tadalafil in their combined pharmaceutical form, demonstrating their sustainability, sensitivity, and suitability for quality assurance, alongside a dissolution study following FDA guidelines.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

Male pattern baldness is largely genetic, linked to the androgen receptor gene, and may relate to certain health issues.

The book explains causes and treatments for common hair loss, its psychological effects, related health risks, and emphasizes early screening and lifestyle changes.

This review discusses the pharmacological properties and clinical applications of cyproterone acetate and similar antiandrogens, noting previous failures in local applications due to concentration limitations; it reports no new empirical results.

This study identified 63 genetic loci associated with male-pattern baldness, uncovering genes and pathways that may help develop treatments and suggesting its connection to other human conditions.

This review summarizes the latest evidence on testosterone, detailing its clinical indications, diagnostic tests, and impacts on various male organs, while also noting its association with aging, metabolic disorders, and increased mortality risk due to androgen deficiency.

This study used machine learning to develop classifiers for identifying effective inhibitors of 5α-reductase isozyme 2, achieving high performance in distinguishing potent from weak inhibitors.

This workshop review from the Australian Hair and Wool Research Society discusses findings in cutaneous biology and endocrinology but presents no new research results.

This review found that androgenetic alopecia may be associated with increased risks of cardiovascular disease, metabolic disorders, and mental health impacts, suggesting its potential as a biomarker for systemic conditions.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.